TY - JOUR
T1 - Multi-country rapid adverse drug event assessment
T2 - The Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study
AU - Pratt, Nicole
AU - Andersen, Morten
AU - Bergman, Ulf
AU - Choi, Nam Kyong
AU - Gerhard, Tobias
AU - Huang, Cecilia
AU - Kimura, Michio
AU - Kimura, Tomomi
AU - Kubota, Kiyoshi
AU - Lai, Edward Chia Cheng
AU - Ooba, Nobuhiro
AU - Ösby, Urban
AU - Park, Byung Joo
AU - Sato, Tsugumichi
AU - Shin, Ju Young
AU - Sundström, Anders
AU - Yang, Yea Huei Kao
AU - Roughead, Elizabeth E.
PY - 2013/9
Y1 - 2013/9
N2 - Purpose: To undertake a multi-country study to investigate the risk of acute hyperglycaemia with antipsychotic use. Methods: Using a distributed network model with a common minimal data set, we performed a prescription sequence symmetry analysis (PSSA) to investigate the risk of acute hyperglycaemia associated with antipsychotic initiation. Incident insulin prescriptions were used as a proxy indicator of acute hyperglycaemia. Participating countries and population datasets included Australia (300,000 persons), Japan I (300,000 persons), Japan II (200,000 persons), Korea (53 million persons) Taiwan (1 million persons), Sweden (9 million persons), USA-Public (87 million persons) and USA-Private (47 million persons). Results: Olanzapine showed a trend towards increased risk in most databases, with a significant association observed in the USA-Public database (Adjusted sequence ratio (ASR)=1.14; 95% Confidence Interval (CI) 1.10-1.17) and Sweden (ASR=1.53; 95% CI 1.13-2.06). Null or negative associations were observed for haloperidol, quetiapine and risperidone. Conclusion: Acute hyperglycaemia appears to be associated with olanzapine use, however, this effect was only observed in two large databases. Despite different patterns of utilization of both antipsychotics and insulin, PSSA analysis results for individual antipsychotic medicines were qualitatively similar across most countries. PSSA, used in conjunction with existing methods, may provide a simple and timely method further supporting multi-national drug safety monitoring.
AB - Purpose: To undertake a multi-country study to investigate the risk of acute hyperglycaemia with antipsychotic use. Methods: Using a distributed network model with a common minimal data set, we performed a prescription sequence symmetry analysis (PSSA) to investigate the risk of acute hyperglycaemia associated with antipsychotic initiation. Incident insulin prescriptions were used as a proxy indicator of acute hyperglycaemia. Participating countries and population datasets included Australia (300,000 persons), Japan I (300,000 persons), Japan II (200,000 persons), Korea (53 million persons) Taiwan (1 million persons), Sweden (9 million persons), USA-Public (87 million persons) and USA-Private (47 million persons). Results: Olanzapine showed a trend towards increased risk in most databases, with a significant association observed in the USA-Public database (Adjusted sequence ratio (ASR)=1.14; 95% Confidence Interval (CI) 1.10-1.17) and Sweden (ASR=1.53; 95% CI 1.13-2.06). Null or negative associations were observed for haloperidol, quetiapine and risperidone. Conclusion: Acute hyperglycaemia appears to be associated with olanzapine use, however, this effect was only observed in two large databases. Despite different patterns of utilization of both antipsychotics and insulin, PSSA analysis results for individual antipsychotic medicines were qualitatively similar across most countries. PSSA, used in conjunction with existing methods, may provide a simple and timely method further supporting multi-national drug safety monitoring.
KW - Antipsychotics
KW - Asian Pharmacoepidemiology Network (AsPEN)
KW - Distributed network model
KW - Hyperglycaemial
KW - Multi-national collaboration
KW - Pharmacoepidemiology
KW - Prescription sequence symmetry analysis
UR - http://www.scopus.com/inward/record.url?scp=84882626723&partnerID=8YFLogxK
U2 - 10.1002/pds.3440
DO - 10.1002/pds.3440
M3 - Article
C2 - 23696036
AN - SCOPUS:84882626723
SN - 1053-8569
VL - 22
SP - 915
EP - 924
JO - Pharmacoepidemiology and Drug Safety
JF - Pharmacoepidemiology and Drug Safety
IS - 9
ER -